Icon - Cancer clinical trials

Cancer clinical trials

A clinical trial is a scientific study or an organised test of medicines and new treatment options involving patient and non-patient volunteers.

The trials confirm whether medicines are safe and effective to introduce as new treatments for a particular disease or condition.

They play a vital role in the search to find better treatments for cancer by testing new or modified treatments and seeing if they are better than existing treatments.

Many people all over the world have taken part in clinical trials that have resulted in improvements to cancer treatment. During a trial, the health and progress of the participants are carefully monitored.

Researchers conducting these trials are hoping to find improved cancer treatments for people with newly diagnosed diseases. Other treatment trials are looking for people who have already been treated for their cancer.

If you have already had one or more forms of cancer treatment and are looking for a new treatment option, there are clinical trials for you to think about.

If you’ve just found out you have cancer, the time to think about joining a trial is before you have any treatment. Ask your oncologist for help in deciding if a clinical trial is right for you.

Go to our Kidney Cancer Support and Information Pack for more resources.

Useful link:  Consumer Guide to Clinical Trials

Considerations

If your doctor suggests you take part in a trial, make sure you fully understand the reasons for the trial and what it means for you. Before making a final decision, you may want to ask these questions:

  • How quickly do you need to make a treatment decision?
  • What treatments are being tested in the trial and why?
  • What tests are involved?
  • What are the possible risks or side effects?
  • How long will the trial last?
  • Will I need to go into hospital for treatment?
  • What will I do if any problems occur while I am in the trial?

The decision to take part in a clinical trial is entirely yours to make. If you decide to participate, you will be given either the best existing treatment or a promising new treatment. The treatment will be allocated at random.

Go to our Kidney Cancer Support and Information Pack for more resources.

Current trials

All efforts have been made to keep this list of clinical trials current; however, as new trials begin, this list may not be all-inclusive. If you are aware of a current or upcoming kidney cancer clinical trial that is not listed, please email us at kidneycancer@kidney.org.au

For more information ask your healthcare team, or consult the Consumer Guide to Clinical Trials.

(Page last updated September 2017)

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies

Purpose: Treatment Trial Phase 2

Cancer Type: Renal cell carcinoma

Stage: Advanced or metastatic RCC

Summary: A Phase 2 study to evaluate the safety and antitumor activity of MEDI0680 in combination with durvalumab versus nivolumab monotherapy in immunotherapy-naïve subjects with advanced or metastatic ccRCC

This study will begin recruiting as of August2017 in New South Wales, Victoria, South Australia and Tasmania. For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02118337

 

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARK-2)

Purpose: Treatment Trial Phase 2

Cancer Type: Renal cell carcinoma with gene rearrangement of NTRK1/2/3/, ROS1, or ALK

Stage: Locally Advanced / Metastatic

Time of treatment:  Two or four weeks post prior therapies

Summary: A phase 2 Basket study of entrectinib for the treatment of patients with solid tumors including renal cell carcinoma that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement.  Patients are assigned to different baskets according to their tumor type and gene rearrangement.  NSCLC and mCRC are the main populations of interest.

This study is currently recruiting in New South Wales (Newcastle Private Hospital) and Victoria (Border Medical Oncology). For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02568267


A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Purpose: Treatment Trial Phase 2

Cancer Type: Renal Medullary Carcinoma

Summary: A phase 2 study of treatment of tazemetostat 800mg BID until disease progression, unacceptable toxicity, withdrawal of consent or termination of the study. Screening is based on 5 cohorts including renal medullary carcinoma.  Response assessment will be evaluated every 8 weeks.

This study is currently recruiting participants in New South Wales (Chris O’Brien Lifehouse). For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT0260195

 

A Study of Atezolizumab in Combination with Bevacizumab Versus Sunitinib in participants with untreated advanced renal cell carcinoma

Purpose:  Treatment trial

Cancer type:  Renal cell carcinoma

Stage:  Inoperable, locally advanced or metastatic renal cell carcinoma

Summary:  A phase 3, randomized, open-label study is designed to evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma.

This study is currently recruiting participants in New South Wales (Camperdown only). It is active but no longer recruiting in New South Wales, Queensland, South Australia, Victoria, Western Australia and Australian Capital Territory. For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02420821


A Study of Avelumab With Axitnib Versus Sunitnib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Purpose:  Treatment Trial Phase 3

Cancer Type: Renal cell carcinoma

Stage: Advanced / Metastatic

Time of treatment:  Disease progression following prior treatment

Summary: A phase 3, randomized trial evaluating the anti- tumor activity and safety of combined Avelumab and Axitinib versus Sunitinib. Administered as first line treatment in patients with advanced renal cancer.

This study is currently recruiting in Victoria. For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02684006


A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE) TCC in the renal pelvis

Purpose:  Treatment Trial Phase 3

Cancer Type: Urothelial cancer in the renal pelvis

Stage: Locally Advanced, Unresectable or Metastatic in the renal pelvis

Time of treatment:  Disease progression following only one prior treatment platinum based in the relapsed or metastatic setting

Summary: A phase 3, double blind, placebo-controlled study to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel with participants with urothelial cancers who have failed platinum based therapy.

This study is currently recruiting in by Eli Lily in New South Wales, Victoria, South Australia and Western Australia. For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02426125

 

CART-WHEEL

CART-WHEEL is an international, ethically approved website that collects information directly from people who are affected by rare tumours and rare subtypes of common cancers. With their permission, this important information can then be accessed by cancer researchers studying rare tumours, giving them access to a larger number of cases and enhancing the quality of their research.

Type:  Any rare tumour or subtype of common cancer

Stage:  Any

Time of treatment:  Any

You can find our more by visiting CART-WHEEL.


CATChEz

Purpose:  Treatment trial

Cancer type:  Renal cell carcinoma

Stage:  Advanced or metastatic (cancer has spread from the kidney to another part in the body)
Time of treatment:  Previously untreated for advanced or metastatic renal cell carcinoma

Summary:  A phase 2, open-label study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma.

This study is active but no longer recruiting. It is active in New South Wales, Queensland, South Australia, Victoria, Western Australia and Australian Capital Territory. For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02601950

 

Focal Ablative Stereotactic Radiotherapy for Cancers of the Kidney (FASTRACK II)


Purpose:  Treatment Trial Phase 2

Cancer Type:  Renal cell carcinoma

Stage:  Local, single lesion in kidney, biopsy confirmed

Time of treatment:  First line treatment.  A multidisciplinary decision for active treatment in either situations of being medically inoperable due to a technical high risk for surgery or declining surgery.

Summary:  To study the safety, efficacy of stereotactic ablative body radiotherapy (SABR) for first line treatment of localised renal cell carcinoma (RCC).

This study is currently recruiting in Victoria (Peter MacCallum Cancer Centre). For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02613819

Forgotten Cancers Project

Cancer Council Victoria invites all Australians over the age of 18 to participate in a national research project. Over the past two to three decades, extensive research has been conducted on common cancers, increasing our understanding of their causes and improving survival. Now is the time to focus on less common cancers. The Forgotten Cancer Project aims to understand the cause of less common cancers such as kidney cancer.

Type:  Any of the ‘forgotten cancers’ including kidney cancer

Stage:  Any stage

Time of treatment:  At any stage of treatment

You can find out more by visiting Forgotten Cancers Project.

 

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Purpose:  Treatment Trial Phase 1

Cancer Type:  Solid Tumor measurable by Response Evaluation Criteria in Solid Tumors (RECIST)

Stage: Advanced / Metastatic

Summary: A phase 1, open-labelled, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in patients with metastatic or locally advanced solid tumors.

This study is currently recruiting in Queensland, New South Wales, Victoria, South Australia and Western Australia. For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02517398

Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Purpose:  Treatment Trial Phase 1

Cancer Type: Renal medullary carcinoma, Rhabdoid tumor of kidney

Stage: Relapsed / Refrahttps://clinicaltrials.gov/ctory INI1-Negative

Summary: A phase 1, open-label, dose escalation and dose expansion study with BD oral dose Tazemetostat.

This study is currently recruiting in Queensland (Lady Cilento Childrens Hospital), New South Wales (Westmead and Sydney Childrens Hospital) and Victoria (Royal Childrens Hospital). For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02601937

 

Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers

Purpose: Treatment Trial Phase 1

Cancer Type: Renal cell carcinoma

Stage: Advanced / Metastatic; Documented Incurable

Time of treatment: Treated with 1 but no more than 5 prior systemic therapies for advanced/recurrent or progressing disease.

Summary: To study the safety, tolerability, and anti-tumor activity of CPI-444 alone and in combination with atezolizumb against various solid tumors including renal cell carcinoma.

This study is currently recruiting in Queensland (Royal Brisbane and Women’s Hospital), New South Wales (Chris O’Brien LifeHouse), Victoria (Monash Health and Peter MacCallum). For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02655822

 

Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy

Purpose:  Treatment Trial,  Phase 3 for metastatic Pain

Cancer Type: Renal cell carcinoma Bone Metastases

Stage: Advanced / Metastatic renal Cell Carcinoma in bones

Summary: A phase 3 study to determine whether Tanezumab is effective in the treatment of cancer pain due to bone metastatses in patients already taking background opioid therapy.

This study is currently recruiting in Victoria (Monash Medical Centre and Ballart Health Services) and South Australia (Flinders Health). For more information visit ClinicalTrials.govClinicalTrials.gov and search the unique trial identification number: NCT02609828


Rare Cancers  Australia

Less common cancers and rare subtypes of cancers are less studied and researched due to smaller patient numbers.

In response to this lack of knowledge, several research projects have been created to improve the understanding of these less common cancers and their causes. Patients, and sometimes their relatives, can contribute to these research projects by sharing their medical information with researchers. Find out more at Rare Cancers Australia site.

 

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Purpose:  Treatment Trial Phase 2

Cancer Type: Solid renal cell carcinoma

Stage: Advanced / Metastatic

Time of treatment:  Disease progression following prior treatment

Summary: A phase 1 and 2, open label trial to study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of drug LAG525 alone and in combination with drug PDR001 to adult patients with solid tumors. 

This study is currently recruiting in New South Wales (Novartis Investigative Site, Westmead) and Victoria (Heidelberg).  For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02460224

 

Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers

Purpose:  Treatment Trial Phase 1/2a

Stage: Advanced

Time of treatment:  Disease progression following prior treatment

Summary: A phase 1/2a study administering a combination of drug: BMS-986205 with Nivolumab in patients with advanced malignant tumors.

This study is currently recruiting in Victoria, and not yet recruiting in New South Wales.   For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02658890


Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for oligometastatic Renal Tumors (RAPPORT)
 (currently not yet recruiting)

Purpose: Treatment Trial

Cancer Type: Renal cell carcinoma

Stage: Advanced / Oligometastases (1-5 metastases)

Time of treatment: Either untreated with advanced/oligometastatic renal cell carcinoma or having received up to 2 lines of systemic treatment eg: Pazopanib or Sunitinib.

Summary: To study the safety, efficacy and biological effects of combining pembrolizumab with stereotactic ablative body radiotherapy (SABR) for oligometastic renal cell carcinoma (RCC).

This study is not yet recruiting. It aims to be available in Queensland (Princess Alexandra Hospital) and Victoria (Oliva Newton-John Cancer Centre). For more information visit ClinicalTrials.gov and search the unique trial identification number: NCT02855203.


Study of Kidney Tumours in Younger Patients

Purpose: Observational study

Cancer type: Renal cell carcinoma

Age: Under 29 years old

Stage: Any

Time of treatment:  Patients with the first occurrence of any tumour of the kidney identified on CT scan or MRI.

Summary:  An observational study following patients over 5 years. The study aims to classify patients with renal tumours in order to define eligibility for a series of therapeutic studies.
This study is currently recruiting participants in New South Wales, Queensland, South Australia, Victoria and Western Australia. For more information visit ClinicTrials.gov and search the unique trial identification number: NCT00898365.

Kidney cancerKidney cancer resources
Join our community to download